Boehringer Ingelheim Corporation's Pradaxa Increases Risk of Heart Attack, Study Shows

Boehringer Ingelheim GmbH’s anti- coagulant Pradaxa increases a patient’s risk of heart attack or severe chest pain, according to a review of studies conducted on the drug. An analysis of seven clinical trials found that it was “significantly associated with a higher risk” of heart attacks and acute coronary syndrome, or ACS, a designation that includes heart attacks and chest pain, researchers wrote in a report published today in the Archives of Internal Medicine. The potential risk of heart attacks could lead doctors to favor Pradaxa’s rivals such as Johnson & Johnson and Bayer AG’s blood-thinner Xarelto in a market Leerink Swann & Co. analysts estimate to be valued at $9 billion a year.

Back to news